Evidence map›Paper›PMID 39422341›Full record

ArticleBioanalysis2024

A comparison of branched DNA and reverse transcriptase quantitative polymerase chain reaction methodologies for quantitation of lipid nanoparticle encapsulated mRNA.

Syed Ali, Matt Bruno, Caleb Celestin, Pratibha Chauhan, Marissa Mitola, Shilpa Sharma, Chiaowen Joyce Hsiao, Mengying Li, Lei Ci, Douglas Burdette and 1 more

Abstract readComparative Study
In one paragraph

Article in Bioanalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Syed AliModerna, Inc., Cambridge, MA 02142, USA.ORCID 0000-0001-7802-4713
Matt BrunoModerna, Inc., Cambridge, MA 02142, USA.ORCID 0009-0004-8280-712X
Caleb CelestinModerna, Inc., Cambridge, MA 02142, USA.ORCID 0009-0005-5100-9237
Pratibha ChauhanModerna, Inc., Cambridge, MA 02142, USA.
Marissa MitolaModerna, Inc., Cambridge, MA 02142, USA.ORCID 0009-0006-8744-2080
Shilpa SharmaModerna, Inc., Cambridge, MA 02142, USA.ORCID 0009-0000-9182-2752
Chiaowen Joyce HsiaoModerna, Inc., Cambridge, MA 02142, USA.ORCID 0000-0001-8961-7522
Mengying LiModerna, Inc., Cambridge, MA 02142, USA.
Lei CiModerna, Inc., Cambridge, MA 02142, USA.
Douglas BurdetteModerna, Inc., Cambridge, MA 02142, USA.
Harkewal SinghModerna, Inc., Cambridge, MA 02142, USA.ORCID 0009-0004-1360-2067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA)-based therapeutics have emerged as a promising modality for various clinical applications, necessitating robust methods for mRNA quantification. This biodistribution study compares the performance of branched DNA and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assays for measuring lipid nanoparticle-encapsulated mRNA. Following intravenous administration of nascent peptide imaging luciferase mRNA (1 mg/kg) to rats, mRNA levels in various tissues and serum were quantified using both assays. Statistical analyses, including Bland-Altman, Deming regression and Passing-Bablok regression, were employed to assess method comparability and reproducibility. The results indicated that mRNA pharmacokinetics measured by branched DNA and RT-qPCR were largely consistent across tissues, with RT-qPCR showing greater reproducibility across multiple laboratories. RT-qPCR also demonstrated a wider dynamic range and higher sensitivity, making it a more versatile option for large-scale studies. Despite some differences in data due to tissue types and timepoints, both methods provided comparable pharmacokinetic profiles for mRNA quantification. This study underscores the importance of selecting an appropriate quantification method based on study requirements and highlights RT-qPCR's adaptability for multisite research, especially for the clinical development of mRNA-based therapeutics.

Indexed as

NanoparticlesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerAnimalsLipidsLiposomesMaleRatsRats, Sprague-DawleyReproducibility of ResultsTissue DistributionLipid NanoparticlesLipidsLiposomesRNA, MessengerbDNA assaybioanalytical techniquesmethod comparisonmRNApharmacokineticsrat biodistribution studyRT-qPCR

Identifiers

PMID39422341
PMCPMC11583626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.